Thirty-day outcome and vascular complications after transarterial aortic valve implantation using both Edwards Sapien™ and Medtronic CoreValve® bioprostheses in a mixed population

Abstract

A routine policy of TAVI using both MCV and ES valves is feasible without any worsening of procedural success rates and 30-day outcomes. A wider population of high risk patients with aortic stenosis can be offered a transarterial treatment. This could be the next standard of care for teams performing TAVI.